Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Retatrutide is developed by Eli Lilly, the company behind tirzepatide (Mounjaro/Zepbound)
Previous or currently active adults are particularly prone to this injury
Ozempic Important Safety Information: Read more about serious warnings and safety info
When nasal spray makes sense Choose nasal spray when: Severe needle phobia (can't overcome) Peptide proven effective nasally (PT-141, Semax) Convenience absolute priority Willing to pay 2-3x more for same effect Traveling frequently (easier to carry) Don't want injection marks Best candidates for nasal: PT-141 users (proven nasal efficacy) Semax/Selank users (designed for nasal) Needle-phobic individuals Infrequent users (as-needed dosing) Those who tried injection and hated it When injection is better Choose injection when: Want maximum efficacy Budget-conscious (2-3x less expensive) Using peptides designed for injection Need consistent results Long-term regular use planned Comfortable with needles (or can learn) Best candidates for injection: Growth hormone peptides (Ipamorelin, CJC-1295) Daily peptide protocols Cost-conscious users Those wanting proven delivery Comparison summary: Hybrid approach: Some use injection primarily Keep nasal spray for travel/convenience Example: Inject BPC-157 , nasal PT-141 Match delivery to peptide and situation See peptide injections guide for injection technique
An analysis of 76 trials found CagriSema outperformed tirzepatide for weight loss
US$ 26.07
US$ 23.25
US$ 25.69
US$ 22.93
US$ 26.22
US$ 20.39
US$ 22.71
US$ 26.41
US$ 22.13
US$ 21.17
